Growth Hormone Treatment Adherence in Prepubertal and Pubertal Children with Different Growth Disorders

Hormone Research in Paediatrics

Volumn 80, Issue 1, 2013, Pages 1-5

  Hartmann, Klaus ^a   Ittner, Jochen ^b   Müller Rossberg, Elke ^c   Schönau, Eckhard ^d   Stephan, Roger ^e   Ullrich, K Peter ^f   Hoppe, Bernd ^g   Ramseger, Rene ^h   Brämswig, Jürgen ⁱ  

^a Medizinisches Kinder und Jugendzentrum für Endokrinologie und Diabetologie ^*  (Germany)

^b Endokrinologische Praxis   (Germany)

^c KLINIKUM ESSLINGEN   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e Kinderärztliche Praxis Dres   (Germany)

^f Fzmb GmbH   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h Merck Serono GmbH   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adherence; Children and adolescents; Compliance; easypod ; Growth hormone treatment; Recombinant human growth hormone; Saizen

Indexed keywords

HUMAN GROWTH HORMONE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; FEMALE; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREPUBERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBERTY; SCHOOL CHILD; SEX DIFFERENCE; SMALL FOR DATE INFANT; TURNER SYNDROME; CHILDHOOD DISEASE; MULTICENTER STUDY; OPEN STUDY; TREATMENT OUTCOME;

EID: 84882448206     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000351800     Document Type: Article

References (26)

1. Ross J, Czernichow P, Biller BM, Colao A, Reiter E, Kiess W: Growth hormone: health considerations beyond height gain. Pediatrics 2010; 125:e906-e918.
2. Raben MS: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 901-903.
3. Flodh H: Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl 1986; 325: 1-9.
4. Zeisel HJ, von Petrykowski W, Wais U: Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. Horm Res 1992; 37(suppl 2):5-13.
5. Richmond E, Rogol AD: Current indications for growth hormone therapy for children and adolescents. Endocr Dev 2010; 18: 92-108.
6. Cole TJ, Hindmarsh PC, Dunger DB: Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency. Arch Dis Child 2004; 89: 1024-1027.
7. Cutfield W, Lindberg A, Albertsson Wikland K, Chatelain P, Ranke MB, Wilton P: Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board. Acta Paediatr Suppl 1999; 88: 72-75.
8. Lanes R: Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol 2004; 3: 53-66.
9. Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E, Hofman PL: Noncompliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011; 6:e16223.
10. Haverkamp F, Johansson L, Dumas H, Langham S, Tauber M, Veimo D, Chiarelli F: Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008; 30: 307-316.
11. Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, Ong KK, Acerini CL: Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008; 93: 147-148.
12. Lustig RH: Optimizing growth hormone efficacy: an evidence-based analysis. Horm Res 2004; 62(suppl 3):93-97.
13. Dahlgren J, Veimo D, Johansson L, Bech I: Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an openlabel, user survey of everyday use. Curr Med Res Opin 2007; 23: 1649-1655.
14. Dahlgren J: Easypod: a new electronic injection device for growth hormone. Expert Rev Med Devices 2008; 5: 297-304.
15. Bozzola M, Colle M, Halldin-Stenlid M, Larroque S, Zignani M: Treatment adherence with the easypod growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents. BMC Endocr Disord 2011; 11: 4.
16. Bundesinstitut für Arnzeimittel und Medizinprodukte. http://www.bfarm.de/EN/BfArM/BfArMService/AMG-en/amg-node-en.html, 2006.
17. Kruse K: Pädiatrische Endokrinologie. Stuttgart, Georg Thieme Verlag, 1999.
18. Rosenfeld RG, Bakker B: Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008; 14: 143-154.
19. Kappelgaard AM, Laursen T: The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age. Growth Horm IGF Res 2011; 21: 305-313.
20. Haverkamp F, Gasteyger C: A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children. J Med Econ 2011; 14: 448-457.
21. Costello K, Kennedy P, Scanzillo J: Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008; 10: 225.
22. Cramer JA: A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218-1224.
23. Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A: Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol 2012; 12: 7.
24. Stanhope R, Albanese A, Moyle L, Hamill G: Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system. Arch Dis Child 1992; 67: 994-997.
25. Adherence to Long-Term Therapies: Evidence for Action. Geneva, World Health Organization, 2003.
26. Norgren S: Adherence remains a challenge for patients receiving growth hormone therapy. Pediatr Endocrinol Rev 2009; 6(suppl 4):545-548.